B. de Valk

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Cardiotoxicity is a side effect of trastuzumab. We assessed efficacy and cardiac safety of CMF with trastuzumab (CMF+T) in HER2-positive metastatic breast cancer patients (MBC). In this phase II study, centrally confirmed, previously treated HER2-positive MBC patients with measurable disease (per RECIST v 1.0) were enrolled. Initially, patients were(More)
Objective: To review the epidemiological and experimental data concerning iron and the development of ath-erosclerosis and ischemic heart disease. Data Sources: The English-language literature was searched from 1981 through 1998 manually and using MEDLINE and Current Contents. Important references in the articles that were found were also included in this(More)
  • 1